Atoltivimab Biosimilar – Anti-Zaire Ebola virus mAb – Research Grade from ProteoGenix; catalogue PX-TA1570; research use only.
Know who made it. See the evidence. Buy through one marketplace.
Atoltivimab Biosimilar is a monoclonal antibody (mAb) that specifically targets the Zaire Ebola virus, a highly infectious and deadly pathogen responsible for multiple outbreaks in Africa. This research-grade antibody is a biosimilar of the original anti-Zaire Ebola virus mAb, and has been developed for scientific research purposes. In this article, we will delve into the structure, activity, and potential applications of Atoltivimab Biosimilar.
Atoltivimab Biosimilar is a recombinant humanized IgG1 monoclonal antibody, with a molecular weight of approximately 150 kDa. It is composed of two identical heavy chains and two identical light chains, each containing a variable region and a constant region. The variable region of the antibody is responsible for binding to the Zaire Ebola virus, while the constant region determines the antibody’s effector functions.
The amino acid sequence of Atoltivimab Biosimilar is highly similar to the original anti-Zaire Ebola virus mAb, with only minor differences due to the biosimilar manufacturing process. These differences do not affect the antibody’s specificity or activity.
Atoltivimab Biosimilar specifically targets the glycoprotein (GP) of the Zaire Ebola virus, which is essential for the virus to enter and infect host cells. The antibody binds to a specific epitope on the GP, preventing its interaction with host cell receptors and thereby inhibiting viral entry.
In addition to its neutralizing activity, Atoltivimab Biosimilar also has effector functions that can aid in the clearance of infected cells. These include antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC), where the antibody binds to infected cells and triggers their destruction by immune cells or complement proteins.
As a research-grade antibody, Atoltivimab Biosimilar can be used in various scientific studies to better understand the Zaire Ebola virus and develop potential treatments. Some potential applications of this antibody include:
1. Studying the mechanism of action of Atoltivimab Biosimilar By using Atoltivimab Biosimilar, researchers can investigate the exact binding site and mechanism of action of the antibody on the Zaire Ebola virus. This can provide valuable insights into the virus-host interaction and help in the development of new therapeutics.
2. Assessing the efficacy of Atoltivimab Biosimilar in animal models Atoltivimab Biosimilar has shown promising results in preclinical studies, and its efficacy can be further evaluated in animal models. This can aid in the development of potential treatments for Ebola virus infections.
3. Screening for potential therapeutic candidates Atoltivimab Biosimilar can also be used in screening assays to identify potential therapeutic candidates that can be developed into novel anti-Zaire Ebola virus treatments. This can involve testing the antibody in combination with other compounds or in different formulations.
4. Studying the immune response to Zaire Ebola virus Atoltivimab Biosimilar can be used to study the immune response to Zaire Ebola virus infection, including the production of neutralizing antibodies. This can provide valuable information for the development of vaccines and other immunotherapies.
Atoltivimab Biosimilar is a highly specific and potent monoclonal antibody that targets the Zaire Ebola virus. Its structure and activity make it a valuable tool for scientific research, with potential applications in studying the virus, developing treatments, and understanding the immune response. As the world continues to face the threat of Ebola virus outbreaks, Atoltivimab Biosimilar could play a crucial role in advancing our knowledge and efforts to combat this deadly pathogen.
ProteoGenix catalogue number PX-TA1570. For research use only.
Target: Atoltivimab Biosimilar – Anti-Zaire Ebola virus mAb – Research Grade; Clonality: Monoclonal Antibody; Expression system: Mammalian cells; Purity: >85%; Buffer: PBS buffer PH7.5; Applications: ELISA, WB.
Available configurations: 50ug, 100ug, 1mg.
Fully tested in-house by ABMIUM, or supported by an advanced validation report from a partner reviewed by ABMIUM. Highest confidence. Non-conformities fully supported under the ABMIUM Product Promise.
Quality verified. Independent collaborator or expected-performance data available. Product meets ABMIUM quality standards.
Expected to work based on structural and biochemical data. Not yet directly tested by ABMIUM or a collaborator. No non-conformity support for this combination.
Not recommended for this application or species/sample combination. This may indicate either evidence of unsuitability or that the combination has not been tested and therefore cannot currently be recommended.
Evidence status by application and model.
| Target | WB | IHC-P | IHC-Fr | IF/ICC | Flow Cyt | IP | ChIP | ELISA |
|---|---|---|---|---|---|---|---|---|
| Atoltivimab Biosimilar – Anti-Zaire Ebola virus mAb – Research Grade |
This product is manufactured by ProteoGenix and sold through ABMIUM without relabelling.
ABMIUM supports global orders. Availability, shipping requirements and applicable import arrangements are confirmed before fulfilment where required.
Yes. Send your target, sample, application and experimental conditions through ABMIUM MATCH or technical support.
Unless the listing expressly states otherwise, ABMIUM products are supplied for research use only and are not for diagnostic or therapeutic use.
